Issue 4, 2020

Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?

Abstract

Globally, schistosomiasis threatens more than 700 million lives, mostly children, in poor localities of tropical and sub-tropical areas with morbidity due to acute and chronic pathological manifestations of the disease. After a century since the first antimonial-based drugs were introduced to treat the disease, anti-schistosomiasis drug development is again at a bottleneck with only one drug, praziquantel, available for treatment purposes. This review focuses on promising chemotypes as potential starting points in a drug discovery effort to meet the urgent need for new schistosomicides.

Graphical abstract: Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?

Article information

Article type
Review Article
Submitted
24 Feb 2020
Accepted
22 Mar 2020
First published
06 Apr 2020

RSC Med. Chem., 2020,11, 455-490

Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?

G. A. Dziwornu, H. D. Attram, S. Gachuhi and K. Chibale, RSC Med. Chem., 2020, 11, 455 DOI: 10.1039/D0MD00062K

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements